Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Olumuyiwa Idowu

Internal Medicine Chicago, IL Medical Doctor

NPI 1538254511 CMS profile 115167

840 W Irving Park Rd, Ste 204, Chicago, IL 60613

Open in the dashboard

General payments

$3,644

97 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$125,032 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Olumuyiwa Idowu of Chicago, IL is reported in the CMS Open Payments database as having received $3,644 across 97 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $125,032 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $719 24
2024 General $1,711 20
2023 General $480 15
2022 General $267 12
2021 General $153 7
2020 General $153 9
2019 General $161 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Olumuyiwa Idowu
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Olumuyiwa Idowu were reported at $719. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Olumuyiwa Idowu Internal Medicine median Middle half National median
2019 $161 $159 $48–$570 $163
2020 $153 $119 $33–$402 $114
2021 $153 $135 $37–$521 $132
2022 $267 $141 $42–$496 $149
2023 $480 $149 $45–$519 $160
2024 $1,711 $154 $47–$537 $164
2025 $719 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Globus Medical, Inc. $1,508 10 payments
  2. Lilly USA, LLC $441 19 payments
  3. Sunovion Pharmaceuticals Inc. $241 14 payments
  4. NuVasive, Inc. $151 1 payment
  5. Organogenesis Inc. $132 6 payments
  6. AstraZeneca Pharmaceuticals LP $123 5 payments
  7. Saxum Surgical, Inc. $122 1 payment
  8. Novo Nordisk Inc $107 6 payments
  9. Pfizer Inc. $103 4 payments
  10. UCB, Inc. $92 4 payments
  11. Other $624 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,499 94 payments
  2. Travel and Lodging $1,144 3 payments
Products named General payments · program years 2019–2025
  1. Captivate VL $1,144 3 payments
  2. JARDIANCE $234 10 payments
  3. TRULICITY $222 11 payments
  4. ACP $214 3 payments
  5. APTIOM $206 11 payments
  6. ALTERA $190 1 payment
  7. Puraply $132 6 payments
  8. Briviact $92 4 payments
  9. Austedo XR $84 3 payments
  10. FARXIGA $84 3 payments
  11. Other $1,129 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 167 drugs

Part D claims

9,448

Median for Internal Medicine: 777

Drug cost

$849,829

Median for Internal Medicine: $73,373

Branded share of claims

23.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 164 $87,042
Aptiom Eslicarbazepine Acetate Brand 130 $83,059
Eliquis Apixaban Brand 248 $81,532
Trulicity Dulaglutide Brand 83 $71,938
Austedo Deutetrabenazine Brand 27 $64,996
Ozempic Semaglutide Brand 41 $62,514
Fanapt Iloperidone Brand 28 $48,591
Breo Ellipta Fluticasone/Vilanterol Brand 72 $32,111
Januvia Sitagliptin Phosphate Brand 60 $30,450
Namzaric Memantine Hcl/Donepezil Hcl Brand 83 $16,726

The 10 drugs with the highest cost, of 167 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$90,790

Of which drugs: $437

Medicare patients

219

Average age 72

Services billed

1,411

108 women, 111 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 53%
Depression 47%
Heart failure 40%
Ischemic heart disease 35%
Chronic kidney disease 33%
Alzheimer's or dementia 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $60
$60 164 —
PAXLOVID
  • PFIZER INC. $48
$48 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $34
$34 16 —
Briviact
  • UCB, Inc. $25
$25 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $25
$25 28 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

97 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record